发明名称 |
LLT-1 antibodies with new functional properties |
摘要 |
The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis. |
申请公布号 |
US9127052(B2) |
申请公布日期 |
2015.09.08 |
申请号 |
US201113807505 |
申请日期 |
2011.06.28 |
申请人 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
发明人 |
Spee Petrus Johannes Louis;Wagtmann Peter Andreas Nicolai Reumert;Zahn Stefan;Galsgaard Elisabeth D.;Friedrichsen Birgitte;Braud Véronique |
分类号 |
C07K16/28;C07K16/18 |
主分类号 |
C07K16/28 |
代理机构 |
Banner & Witcoff, Ltd. |
代理人 |
Banner & Witcoff, Ltd. |
主权项 |
1. A monoclonal antibody which specifically binds to lectin-like transcript 1 (LLT1), wherein the LLT1 comprises SEQ ID NO:1, wherein:
the heavy chain of said antibody comprises:
a CDR1 sequence of amino acids 31 to 35 (SYGMS) of SEQ ID NO:4;a CDR2 sequence of amino acids 50 to 66 (TINSNGGRTFYPDSVKG) of SEQ ID NO:4;a CDR3 sequence of amino acids 99 to 108 (DGGYWAHFDY) of SEQ ID NO:4; and the light chain of said antibody comprises:
a CDR1 sequence of amino acids 24 to 40 (RSSQSIVHSNGNTYLE) of SEQ ID NO:7;a CDR2 sequence of amino acids 56 to 62 (KVSNRFS) of SEQ ID NO:7; anda CDR3 sequence of amino acids 94 to 102 (FQGSHVPWT) of SEQ ID NO:7. |
地址 |
Paris FR |